TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2021 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
TXMD on Nasdaq
Shares outstanding
11,549,491
Price per share
$1.64
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
3,303,788
Total reported value
$3,542,705
% of total 13F portfolios
0%
Share change
+48,161
Value change
+$51,253
Number of holders
43
Price from insider filings
$1.64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Clearline Capital LP 5.5% $705,096 635,222 Clearline Capital LP 31 Dec 2024

As of 30 Sep 2025, 43 institutional investors reported holding 3,303,788 shares of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD). This represents 29% of the company’s total 11,549,491 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) together control 29% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Rubric Capital Management LP 10% 1,192,191 0% 0.02% $1,281,605
Clearline Capital LP 5.5% 635,222 0% 0.06% $682,864
VANGUARD GROUP INC 3.3% 376,828 -0.57% 0% $399,437
Tejara Capital Ltd 3% 344,203 -0.01% 0.2% $370,018
ADAR1 Capital Management, LLC 1.8% 209,210 0% 0.02% $224,901
MORGAN STANLEY 1.1% 130,572 -0.49% 0% $140,365
BlackRock, Inc. 1% 116,132 0% 0% $124,842
GEODE CAPITAL MANAGEMENT, LLC 0.94% 109,083 0% 0% $115,656
RENAISSANCE TECHNOLOGIES LLC 0.31% 35,500 +138% 0% $38,163
CITADEL ADVISORS LLC 0.3% 34,273 0% $36,329
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.29% 34,000 0% 0% $36,040
STATE STREET CORP 0.26% 30,100 0% 0% $31,906
NORTHERN TRUST CORP 0.14% 16,457 0% 0% $17,691
J. Goldman & Co LP 0.12% 13,562 0% 0% $14,579
TWO SIGMA SECURITIES, LLC 0.1% 11,967 +15% 0% $12,865
FMR LLC 0.07% 8,289 0% 0% $8,786
Tower Research Capital LLC (TRC) 0.02% 2,733 -5.2% 0% $2,938
OSAIC HOLDINGS, INC. 0.01% 897 +4.2% 0% $972
NATIONAL BANK OF CANADA /FI/ 0.01% 670 -5.6% 0% $710
UBS Group AG 0% 362 -92% 0% $390
JPMORGAN CHASE & CO 0% 293 0% 0% $310
SBI Securities Co., Ltd. 0% 255 0% 0% $274
US BANCORP \DE\ 0% 246 0% 0% $264
BNP PARIBAS FINANCIAL MARKETS 0% 226 0% 0% $243
HUNTINGTON NATIONAL BANK 0% 120 0% 0% $129

Institutional Holders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 3,303,788 $3,542,705 +$51,253 $1.08 43
2025 Q2 3,255,627 $3,776,528 -$96,760 $1.16 39
2025 Q1 3,343,589 $3,092,849 -$161,728 $0.92 39
2024 Q4 3,528,745 $3,034,778 +$127,744 $0.86 38
2024 Q3 3,379,026 $5,609,223 -$32,659 $1.66 34
2024 Q2 3,408,566 $5,487,879 -$167 $1.61 34
2024 Q1 3,377,053 $7,732,812 +$286,534 $2.29 43
2023 Q4 3,251,877 $7,316,577 -$358,133 $2.25 36
2023 Q3 2,987,555 $9,324,433 +$112,168 $3.02 36
2023 Q2 3,031,054 $12,488,021 -$296,992 $4.12 40
2023 Q1 3,115,140 $11,682,289 -$1,635,363 $3.75 38
2022 Q4 3,475,915 $19,431,091 +$6,039,029 $5.59 43
2022 Q3 2,070,807 $13,750,198 -$489,469 $6.64 29
2022 Q2 1,993,507 $19,835,726 +$19,831,622 $9.95 36
2022 Q1 10,800 $4,104 +$304 $0.38 2
2021 Q4 10,000 $3,555 $0.36 1